This inventor holds 1 USPTO granted patent. Top assignees: La Jolla Institute for Immunology, Massachusetts Institute of Technology. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2 
1 out of 8,594 
Years Active: 2025
Title: Innovator Spotlight: Yu Kato and His Contributions to Vaccine Development
Introduction: Yu Kato, an inventive mind based in San Diego, CA, has made significant strides in the field of vaccine research. With one patent to his name, Kato's work focuses on advancing immunology through innovative approaches to vaccine adjuvants.
Latest Patents: Kato's notable patent, titled "Nanoparticle vaccine adjuvant and methods of use thereof," introduces a novel composition comprising non-liposome, non-micelle particles. These particles are formulated from a lipid and an additional adjuvant, including TLR4 agonists, sterols, and saponins. The innovative particles, described as porous, cage-like nanoparticles or nanocages, vary between approximately 30 nm and 60 nm. Their incorporation can lead to enhanced immune responses, making them especially valuable as adjuvants in vaccine applications.
Career Highlights: Throughout his career, Yu Kato has been associated with prestigious institutions, including the Massachusetts Institute of Technology (MIT) and the La Jolla Institute for Immunology. His experiences at these research powerhouses have facilitated his development of cutting-edge technologies in immunotherapy and vaccine design. Kato's contributions have not only expanded scientific knowledge but have also paved the way for potential advancements in public health.
Collaborations: Kato's innovative work has involved collaboration with other esteemed researchers, including Darrell J. Irvine and Murillo Silva. These partnerships exemplify the importance of teamwork in driving scientific discovery and the development of effective therapeutic solutions.
Conclusion: Yu Kato stands out as a key innovator in the field of vaccine research. His pioneering patent on nanoparticle vaccine adjuvants highlights the potential of new materials to enhance immune responses. As Kato continues to push the boundaries of scientific research, his work may lead to significant improvements in vaccine efficacy and public health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile